Compare · IQV vs SLGC
IQV vs SLGC
Side-by-side comparison of IQVIA Holdings Inc. (IQV) and SomaLogic Inc. (SLGC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IQV and SLGC operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- IQV is the larger of the two at $30.62B, about 21.4x SLGC ($1.43B).
- IQV has hit the wire 5 times in the past 4 weeks while SLGC has been quiet.
- IQV has more recent analyst coverage (25 ratings vs 6 for SLGC).
- Company
- IQVIA Holdings Inc.
- SomaLogic Inc.
- Price
- $182.90-0.29%
- $2.09-5.43%
- Market cap
- $30.62B
- $1.43B
- 1M return
- +2.14%
- -
- 1Y return
- +18.70%
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NYSE
- NASDAQ
- IPO
- 2013
- 2021
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 6
IQVIA Holdings Inc.
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Latest IQV
- SEC Form 8-K filed by IQVIA Holdings Inc.
- IQVIA Announces Pricing of Senior Notes
- SEC Form 8-K filed by IQVIA Holdings Inc.
- IQVIA Announces Offering of Senior Notes
- IQVIA CEO to Speak at Jefferies Global Healthcare Conference
- IQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled Capabilities
- SEC Form 4 filed by Director Wims Morris Leslie
- SEC Form 4 filed by Director Goggins Colleen A
- SEC Form 4 filed by Director Fasano Jim
- SEC Form 4 filed by Director Danhakl John G
Latest SLGC
- OncoHost Selected to Present in Oral Minisymposium at American Association of Cancer Research (AACR) Annual Meeting 2024
- SEC Form SC 13G/A filed by SomaLogic Inc. (Amendment)
- SEC Form SC 13G/A filed by SomaLogic Inc. (Amendment)
- SEC Form 15-12G filed by SomaLogic Inc.
- SEC Form EFFECT filed by SomaLogic Inc.
- SEC Form EFFECT filed by SomaLogic Inc.
- Taich Adam returned 48,425 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Ryan Jason
- Roelke Alison Marie returned 17,143 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Post Richard A returned 57,430 shares to the company, closing all direct ownership in the company (SEC Form 4)